ArticleGynecologic oncology2009
CD83 polymorphisms and cervical cancer risk.
Article in Gynecologic oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Integrating Biomarkers into Cervical Cancer Screening-Advances in Diagnosis and Risk Prediction: A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Distribution of DC Subtypes: CD83+, DC-LAMP+, CD1a+, CD1c+, CD123+, and DC-SIGN+ in the Tumor Microenvironment of Endometrial Cancers-Correlation with Clinicopathologic Features.International journal of molecular sciences · 2023Article
- Multi-omics mapping of human papillomavirus integration sites illuminates novel cervical cancer target genes.British journal of cancer · 2021Article
- Genomic Risk Factors for Cervical Cancer.Cancers · 2021Review
- CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential.Frontiers in immunology · 2019Review
- Nucleotide variation inOncology letters · 2018Article
- Defining the genetic susceptibility to cervical neoplasia-A genome-wide association study.PLoS genetics · 2017Article
- Novel Somatic Copy Number Alteration Identified for Cervical Cancer in the Mexican American Population.Medical sciences (Basel, Switzerland) · 2016Article
- Polymorphisms in immune mediators associate with risk of cervical cancer.Gynecologic oncology · 2014Article
- Genetic variations in EGFR and ERBB4 increase susceptibility to cervical cancer.Gynecologic oncology · 2013Article
- CD83 antigen expression and its role in the progression of systemic malignancies.Sao Paulo medical journal = Revista paulista de medicina · 2013Article
- Article
- Genetic variation in CD83 and risks of cervical and vulvar cancers: a population-based case-control study.Gynecologic oncology · 2012Article
- Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2012Article
- TP53, MDM2, NQO1, and susceptibility to cervical cancer.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesStudies have suggested that polymorphisms in genes involved in immune recognition and antigen presentation are associated with cervical cancer risk. We sought to replicate a recent study which reported an association between specific SNPs on CD83 and cervical cancer and to further explore whether effects varied by age, clinical stage (in situ versus invasive), and histology (squamous carcinomas versus adenocarcinomas).
methodsWe evaluated the association between SNPs on CD83 and cervical cancer in a multicenter case-control study of cervical cancer conducted in the Eastern United States (263 cases, 307 controls), focusing on the five SNPs (RS9296925, RS853360, RS9230, RS9370729, RS750749) previously found to be associated with cervical cancer. We also pooled data from the Eastern U.S. (263 cases) with those from the original report (377 cases) to assess the effects of CD83 on the age at diagnosis, disease stage, and histology. Risk estimates (ORs) and 95% confidence intervals were estimated using logistic regression; trend tests were performed under an additive model.
resultsConsistent with the original report, carriers of the CT or CC genotypes for one of the five CD83 SNPs evaluated (rs750749) demonstrated a 30% and 50% reduction in disease risk, relative to carriers of the more common TT genotype (p-trend=0.02). Two additional SNPs also resulted in consistent findings (rs9296925: p-trend=0.07 and rs9370729: p-trend=0.08), although the effects observed did not reach statistical significance at the 0.05 level. Pooled evaluation of cases from the two aforementioned studies suggested differences in the distribution of susceptibility alleles by histology; adenocarcinoma cases were more likely to be carriers of the susceptibility alleles for SNP rs9370729 (p-trend=0.02) and SNP rs750749 (p-trend=0.09). No differences were observed in the age or stage of diagnosis of carriers for CD83 susceptibility alleles relative to non-carriers.
conclusionsWe confirm an association between CD83 polymorphisms and cervical cancer and suggest the possibility that CD83-disease associations might be heterogenous by tumor histology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.